The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).
|Original language||English (US)|
|Number of pages||1|
|State||Published - Feb 25 2016|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)